Market Size in 2019 | Market Forecast in 2026 | CAGR (in %) | Base Year |
---|---|---|---|
USD 927.9 Million | USD 1,601.6 Million | 8.2% | 2019 |
The global hunter syndrome treatment market size was worth around $927.9 Million in 2019 and is predicted to grow to around $1,601.6 Million by 2026 with a compound annual growth rate (CAGR) of roughly 8.2% between 2019 and 2026.
The report analyzes the global hunter syndrome treatment market drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the global hunter-syndrome treatment industry.
The report covers forecasts and analyses for the Hunter syndrome treatment market on a global and regional level. The study provides historic data from 2016 to 2019 along with a forecast from 2020 to 2026 based on revenue (USD Million). The study includes drivers and restraints for the Hunter syndrome treatment market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the hunter syndrome treatment market on a global as well as regional level.
In order to give the users of this report a comprehensive view of the hunter syndrome treatment market we have included a competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all segments are benchmarked based on their market size, growth rate, and general attractiveness.
The report provides a company market share analysis in order to give a broader overview of the key players in the hunter syndrome treatment market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new indication launches, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the hunter syndrome treatment market on a global and regional basis.
The study provides a crucial view of the Hunter syndrome treatment by segmenting the market based on treatment and region. All the segments of the Hunter syndrome treatment market have been analyzed based on present and future trends and the market is estimated from 2016 to 2026.
The global demand for the Hunter syndrome treatment market is driven by the expected approval of new therapies, growing research and development activities, and extended life expectancy. However, lack of awareness and high cost may act as restraining factors for the market growth in the coming years. Increasing collaboration and technological advancements are projected to bring new growth avenues for market players during the forecast timeframe.
The Hunter syndrome treatment market has been divided into treatment and region. Based on treatment, the global Hunter syndrome treatment market is segmented into Hematopoietic Stem Cell Transplant (HSCT), Enzyme Replacement Therapy (ERT), and others. The market was dominated by the Enzyme Replacement Therapy (ERT) segment in 2019 and is projected to retain its dominance over the forecast timeframe.
Report Attributes | Report Details |
---|---|
Report Name | Hunter Syndrome Treatment Market Research Report |
Market Size in 2019 | USD 927.9 Million |
Market Forecast in 2026 | USD 1,601.6 Million |
Growth Rate | CAGR of 8.2% |
Number of Pages | 255 |
Forecast Units | Value (USD Billion), and Volume (Units) |
Key Companies Covered | GC Pharma, Takeda Pharmaceutical Company, RegenxBio Inc., JCR Pharmaceuticals Co Ltd., Sangamo Therapeutics, Inc., Inventiva S.A., ArmaGen Inc, Esteve, Bioasis Technologies Inc., Denali Therapeutics Inc among others. |
Segments Covered | By Treatment, And By Region |
Regions Covered | North America, Europe, Asia Pacific (APAC), Latin America, Middle East and Africa (MEA) |
Base Year | 2019 |
Historical Year | 2016 to 2019 |
Forecast Year | 2020 - 2026 |
Customization Scope | Avail customized purchase options to meet your exact research needs. Request For Customization |
North America held the largest revenue share of the global hunter syndrome treatment market in 2018. This large share is attributed to government funding, growing awareness, and the presence of key players in this region. Europe was second leading regional market in terms of revenue. Availability of developed infrastructure, increasing geriatric population, and growing awareness are major factors that support market growth in this region.
Asia Pacific region is projected to be a rapidly growing regional market for hunter syndrome treatment. Increasing chronic disease prevalence and geriatric population base, economic development, improvement of healthcare infrastructure, and growing awareness are major factors attributing to the swift growth in this region. Moderate growth is projected in the Latin America region over the forecast period. Middle East and Africa will witness sluggish growth in the coming years.
Major players in the Hunter syndrome treatment market are
Global Hunter Syndrome Treatment Market: Treatment
Global Hunter Syndrome Treatment Market: By Region
FrequentlyAsked Questions
Hunter syndrome, commonly known as mucopolysaccharidosis II (MPS II), is a rare genetic condition characterized by iduronate-2-sulfatase deficiency. This deficit causes glycosaminoglycans to accumulate in cells, creating a variety of progressive and debilitating symptoms.
The global demand for hunter syndrome treatment market is driven by expected approval of new therapies, growing research and development activities, and extended life expectancy.
According to the report, global demand for hunter syndrome treatment market was valued at approximately USD 927.9 million in 2019, and is expected to generate revenue of around USD 1,601.6 million by end of 2026, growing at a CAGR of around 8.2% between 2020 and 2026.
North America held largest revenue share of the global hunter syndrome treatment market in 2018. This large share is attributed to government funding, growing awareness and presence of key players in this region.
Major players in hunter syndrome treatment market are GC Pharma, Takeda Pharmaceutical Company, RegenxBio Inc., JCR Pharmaceuticals Co Ltd., Sangamo Therapeutics, Inc., Inventiva S.A., ArmaGen Inc, Esteve, Bioasis Technologies Inc., and Denali Therapeutics Inc among others.
RelatedNews
HappyClients
Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651
3rd Floor,
Mrunal Paradise, Opp Maharaja Hotel,
Pimple Gurav, Pune 411061,
Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008
US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com
We have secured system to process your transaction.
Our support available to help you 24 hours a day, five days a week.
Monday - Friday: 9AM - 6PM
Saturday - Sunday: Closed